CN101687022B - Prame衍生的肽以及包括该肽的免疫原组合物 - Google Patents
Prame衍生的肽以及包括该肽的免疫原组合物 Download PDFInfo
- Publication number
- CN101687022B CN101687022B CN200880009876.5A CN200880009876A CN101687022B CN 101687022 B CN101687022 B CN 101687022B CN 200880009876 A CN200880009876 A CN 200880009876A CN 101687022 B CN101687022 B CN 101687022B
- Authority
- CN
- China
- Prior art keywords
- peptide
- hla
- epi
- prame
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 284
- 108060006580 PRAME Proteins 0.000 title claims abstract description 129
- 102000036673 PRAME Human genes 0.000 title claims abstract description 129
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 230000002163 immunogen Effects 0.000 title description 9
- 235000001014 amino acid Nutrition 0.000 claims abstract description 83
- 150000001413 amino acids Chemical class 0.000 claims abstract description 83
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 50
- 201000011510 cancer Diseases 0.000 claims abstract description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 68
- 229960005486 vaccine Drugs 0.000 claims description 32
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 31
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 31
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 25
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 25
- 230000004913 activation Effects 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 13
- 238000005520 cutting process Methods 0.000 claims description 13
- 102000002689 Toll-like receptor Human genes 0.000 claims description 7
- 108020000411 Toll-like receptor Proteins 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 42
- 239000003814 drug Substances 0.000 abstract description 11
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 107
- 230000004044 response Effects 0.000 description 40
- 238000000034 method Methods 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 230000006698 induction Effects 0.000 description 19
- 210000004443 dendritic cell Anatomy 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 102100031293 Thimet oligopeptidase Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108010073106 thimet oligopeptidase Proteins 0.000 description 10
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000002443 helper t lymphocyte Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 8
- 108010039075 HLA-B8 Antigen Proteins 0.000 description 8
- 102100021850 Nardilysin Human genes 0.000 description 8
- 108090000970 Nardilysin Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- -1 HLA-A68 Proteins 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000003702 retinoic acid receptors Human genes 0.000 description 6
- 108090000064 retinoic acid receptors Proteins 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 5
- 108010012145 HLA-B61 antigen Proteins 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 4
- 108010004141 HLA-B35 Antigen Proteins 0.000 description 4
- 108010055587 HLA-B60 antigen Proteins 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- AOZUYISQWWJMJC-UHFFFAOYSA-N acetic acid;methanol;hydrate Chemical compound O.OC.CC(O)=O AOZUYISQWWJMJC-UHFFFAOYSA-N 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000010183 spectrum analysis Methods 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 108010036972 HLA-A11 Antigen Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 108010032563 oligopeptidase Proteins 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- DLQPMEMYCIGJIM-UHFFFAOYSA-N Adjuvant peptide Natural products CC(NC(=O)CCOC1C(O)C(CO)OC(O)C1NC(=O)C)C(=O)NC(CCC(=O)O)C(=O)N DLQPMEMYCIGJIM-UHFFFAOYSA-N 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100021598 Endoplasmic reticulum aminopeptidase 1 Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006390 HLA-B Antigens Human genes 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000898750 Homo sapiens Endoplasmic reticulum aminopeptidase 1 Proteins 0.000 description 1
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 1
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013502 data validation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- BSOQXXWZTUDTEL-QAQREVAFSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-QAQREVAFSA-N 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464489—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610596359.9A CN106220721B (zh) | 2007-03-26 | 2008-03-26 | Prame衍生的肽以及包括该肽的免疫原组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07104893.8 | 2007-03-26 | ||
EP07104893 | 2007-03-26 | ||
PCT/NL2008/050171 WO2008118017A2 (en) | 2007-03-26 | 2008-03-26 | Prame derived peptides and immunogenic compositions comprising these |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610596359.9A Division CN106220721B (zh) | 2007-03-26 | 2008-03-26 | Prame衍生的肽以及包括该肽的免疫原组合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN101687022A CN101687022A (zh) | 2010-03-31 |
CN101687022A8 CN101687022A8 (zh) | 2016-08-24 |
CN101687022B true CN101687022B (zh) | 2016-09-07 |
Family
ID=38267662
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880009876.5A Expired - Fee Related CN101687022B (zh) | 2007-03-26 | 2008-03-26 | Prame衍生的肽以及包括该肽的免疫原组合物 |
CN201610596359.9A Expired - Fee Related CN106220721B (zh) | 2007-03-26 | 2008-03-26 | Prame衍生的肽以及包括该肽的免疫原组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610596359.9A Expired - Fee Related CN106220721B (zh) | 2007-03-26 | 2008-03-26 | Prame衍生的肽以及包括该肽的免疫原组合物 |
Country Status (8)
Country | Link |
---|---|
US (3) | US8492514B2 (zh) |
EP (3) | EP3533461A3 (zh) |
JP (2) | JP5649952B2 (zh) |
CN (2) | CN101687022B (zh) |
AU (1) | AU2008230240B2 (zh) |
CA (2) | CA2681132C (zh) |
ES (1) | ES2539812T3 (zh) |
WO (1) | WO2008118017A2 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869682B (zh) | 2009-11-18 | 2016-10-19 | 曼康公司 | 单克隆抗体及其诊断用途 |
NL2007536C2 (en) | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
JP6366580B2 (ja) * | 2012-06-22 | 2018-08-01 | エイチティージー モレキュラー ダイアグノスティクス, インコーポレイテッド | メラニン細胞性病変における分子悪性度 |
CA2953747A1 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
AU2014298504B2 (en) * | 2013-07-30 | 2018-08-30 | Biontech Ag | Tumor antigens for determining cancer therapy |
WO2016103192A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
EP3297673A4 (en) * | 2015-05-22 | 2019-05-08 | Memorial Sloan-Kettering Cancer Center | FOR A PRAME-PEPTIDE SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES |
EP3112375A1 (en) * | 2015-07-03 | 2017-01-04 | Ludwig-Maximilians-Universität München | Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris |
CN106519019B (zh) * | 2015-11-06 | 2018-07-03 | 广东香雪精准医疗技术有限公司 | 识别prame抗原的tcr |
CN106831978B (zh) * | 2015-12-04 | 2020-05-26 | 中国科学院广州生物医药与健康研究院 | 识别prame抗原的t细胞受体 |
MY196837A (en) * | 2015-12-11 | 2023-05-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
EA201891639A1 (ru) | 2016-02-26 | 2019-06-28 | Окленд Юнисервисес Лимитед | Аминокислотные и пептидные конъюгаты и способ конъюгации |
CN106699874B (zh) * | 2016-03-29 | 2018-06-05 | 广东香雪精准医疗技术有限公司 | 识别prame抗原短肽的t细胞受体 |
CN107266552B (zh) * | 2016-03-30 | 2022-02-08 | 香雪生命科学技术(广东)有限公司 | 源自于prame的肿瘤抗原短肽 |
US10702598B2 (en) | 2016-06-20 | 2020-07-07 | Isa Pharmaceuticals B.V. | Formulation of a peptide vaccine |
CN108203459A (zh) * | 2016-12-19 | 2018-06-26 | 广东香雪精准医疗技术有限公司 | 源自于prame的肿瘤抗原短肽 |
CN108203460B (zh) * | 2016-12-19 | 2021-10-08 | 香雪生命科学技术(广东)有限公司 | 衍生自肿瘤抗原prame的短肽 |
CN108264550B (zh) * | 2017-01-04 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别源自于prame抗原短肽的tcr |
HRP20230512T8 (hr) * | 2017-01-27 | 2023-09-15 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma |
NL2018803B1 (en) | 2017-04-27 | 2018-11-05 | Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc | Adjuvant compounds |
CN108929378B (zh) * | 2017-05-22 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别prame抗原的t细胞受体及编码该受体的核酸 |
GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
KR20200033936A (ko) * | 2017-08-02 | 2020-03-30 | 아이디피 디스커버리 파마, 에스.엘. | 항암 펩타이드 |
CN109400696B (zh) * | 2017-08-17 | 2021-04-23 | 香雪生命科学技术(广东)有限公司 | 一种识别prame抗原短肽的tcr |
HUE061198T2 (hu) * | 2017-12-13 | 2023-05-28 | Inovio Pharmaceuticals Inc | A PRAME-t célzó rákvakcinák és alkalmazásaik |
CA3223357A1 (en) | 2021-07-12 | 2023-01-19 | Brigitte Elisa Anna Burm | Improved substance quantification in complex mixtures |
WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
WO2024079311A1 (en) | 2022-10-13 | 2024-04-18 | Isa Pharmaceuticals B.V. | Modified long peptides suitable for use in immunisation |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830753A (en) | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
DK1082141T3 (da) | 1998-05-23 | 2005-12-05 | Univ Leiden Medical Ct | CD40-bindende molekyler og CTL-peptider til behandling af tumorer |
US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
US20020049312A1 (en) * | 2000-05-23 | 2002-04-25 | Turner C. Alexander | Noel human thrombospondin-like proteins and polynucleotides encoding the same |
FR2804117B1 (fr) | 2000-01-21 | 2004-08-20 | Bio Merieux | Procede d'isolement de proteines et/ou d'acides nucleiques, complexes de particules et de proteines et/ou d'acides nucleiques, reactif et applications |
EP1118860A1 (en) | 2000-01-21 | 2001-07-25 | Rijksuniversiteit te Leiden | Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes |
AUPQ776100A0 (en) * | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
ES2519043T3 (es) | 2000-12-08 | 2014-11-06 | Academisch Ziekenhuis Leiden | Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos |
WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
MXPA04009554A (es) * | 2002-04-01 | 2005-01-25 | Euro Celtique Sa | Construcciones epitopes que comrpenden antigeno presentando mecanismos de marcacion celular. |
JP2005537800A (ja) * | 2002-09-06 | 2005-12-15 | マンカインド コーポレイション | エピトープ配列 |
US20080274129A1 (en) * | 2003-04-18 | 2008-11-06 | Fikes John D | Hla-A2 Tumor Associated Antigen Peptides and Compositions |
MXPA05013973A (es) * | 2003-06-17 | 2006-03-02 | Mannkind Corp | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. |
US7340702B2 (en) * | 2003-07-23 | 2008-03-04 | Cadence Design Systems, Inc. | Method and apparatus for induction proof |
AU2005265182B2 (en) | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
EP2385060A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
EP2371851A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
-
2008
- 2008-03-26 ES ES08723922.4T patent/ES2539812T3/es active Active
- 2008-03-26 EP EP19162264.6A patent/EP3533461A3/en not_active Withdrawn
- 2008-03-26 CN CN200880009876.5A patent/CN101687022B/zh not_active Expired - Fee Related
- 2008-03-26 AU AU2008230240A patent/AU2008230240B2/en not_active Ceased
- 2008-03-26 JP JP2010500861A patent/JP5649952B2/ja active Active
- 2008-03-26 WO PCT/NL2008/050171 patent/WO2008118017A2/en active Application Filing
- 2008-03-26 CA CA2681132A patent/CA2681132C/en active Active
- 2008-03-26 EP EP11193328.9A patent/EP2462947B1/en not_active Not-in-force
- 2008-03-26 EP EP08723922.4A patent/EP2125005B1/en active Active
- 2008-03-26 CA CA2996732A patent/CA2996732C/en active Active
- 2008-03-26 CN CN201610596359.9A patent/CN106220721B/zh not_active Expired - Fee Related
-
2009
- 2009-09-24 US US12/586,625 patent/US8492514B2/en active Active
-
2013
- 2013-07-18 US US13/945,335 patent/US9441025B2/en active Active
-
2014
- 2014-08-01 JP JP2014158054A patent/JP5985551B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-04 US US15/228,234 patent/US10450356B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2010522748A (ja) | 2010-07-08 |
WO2008118017A3 (en) | 2008-12-31 |
CN106220721A (zh) | 2016-12-14 |
US10450356B2 (en) | 2019-10-22 |
JP5649952B2 (ja) | 2015-01-07 |
CA2996732C (en) | 2020-10-27 |
CA2681132C (en) | 2018-05-01 |
CA2681132A1 (en) | 2008-10-02 |
EP3533461A2 (en) | 2019-09-04 |
CN106220721B (zh) | 2020-04-07 |
EP2462947A1 (en) | 2012-06-13 |
JP2014240407A (ja) | 2014-12-25 |
US8492514B2 (en) | 2013-07-23 |
EP3533461A3 (en) | 2019-12-18 |
WO2008118017A2 (en) | 2008-10-02 |
US9441025B2 (en) | 2016-09-13 |
AU2008230240A1 (en) | 2008-10-02 |
CN101687022A (zh) | 2010-03-31 |
JP5985551B2 (ja) | 2016-09-06 |
ES2539812T3 (es) | 2015-07-06 |
US20160333065A1 (en) | 2016-11-17 |
CA2996732A1 (en) | 2008-10-02 |
EP2125005B1 (en) | 2015-04-08 |
US20140348862A1 (en) | 2014-11-27 |
CN101687022A8 (zh) | 2016-08-24 |
US20100120683A1 (en) | 2010-05-13 |
AU2008230240B2 (en) | 2012-09-13 |
EP2125005A2 (en) | 2009-12-02 |
EP2462947B1 (en) | 2019-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101687022B (zh) | Prame衍生的肽以及包括该肽的免疫原组合物 | |
CN102892777B (zh) | 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物 | |
CN103394079B (zh) | 癌症疫苗组合物 | |
CN101711280B (zh) | Tem8肽和包含tem8肽的疫苗 | |
Buteau et al. | Challenges in the development of effective peptide vaccines for cancer | |
CN108383894A (zh) | 多肽及其应用 | |
CN102947325B (zh) | Cdca5肽及包含它们的疫苗 | |
CN105164256A (zh) | Kntc2肽及包含它们的疫苗 | |
DK2771350T3 (en) | TOP PEPTIDES AND VACCINES INCLUDING THESE | |
CN103732743A (zh) | Mphosph1肽及包含它们的疫苗 | |
CN103339253A (zh) | Tomm34肽及包含它们的疫苗 | |
AU2011233401B2 (en) | ECT2 peptides and vaccines including the same | |
CN104193816A (zh) | C1orf59肽及包含它的疫苗 | |
AU2011225577A1 (en) | HJURP peptides and vaccines including the same | |
US9056890B2 (en) | WDHD1 peptides and vaccines including the same | |
US20130287805A1 (en) | C18orf54 peptides and vaccines including the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CI01 | Publication of corrected invention patent application |
Correction item: Third inventor Correct: C - J - M - Meilifu False: Melief Cornelis Johannes Maria Number: 13 Volume: 26 |
|
CI02 | Correction of invention patent application |
Correction item: Third inventor Correct: C - J - M - Meilifu False: Melief Cornelis Johannes Maria Number: 13 Page: The title page Volume: 26 |
|
ERR | Gazette correction | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160907 |